Literature DB >> 28510689

Chronic Enteropathy Associated With SLCO2A1 Gene [CEAS]-Characterisation of an Enteric Disorder to be Considered in the Differential Diagnosis of Crohn's Disease.

Naoki Hosoe1, Naoki Ohmiya2, Fumihito Hirai3, Junji Umeno4, Motohiro Esaki4, Hirokazu Yamagami5, Kei Onodera6, Shigeki Bamba7, Hiroyuki Imaeda8, Shunichi Yanai9, Tadakazu Hisamatsu10, Haruhiko Ogata1, Takayuki Matsumoto9.   

Abstract

Small intestinal ulcers include mucosal damage caused by drugs, particularly nonsteroidal anti-inflammatory drugs [NSAIDs], infectious diseases, and idiopathic inflammatory bowel disease. Previously, a group of Japanese investigators reported an unusual and uncommon type of enteritis and referred to the condition as chronic nonspecific multiple ulcers of the small intestine [CNSU]. CNSU is characterised by chronic blood and protein loss through persistent small intestinal ulcers. Recently, four candidate mutations in the solute carrier organic anion transporter family, member 2A1 [SLCO2A1] gene, encoding a prostaglandin transporter, were identified by whole-exome sequencing in patients with CNSU. However, because the name 'CNSU' was somewhat ambiguous, the more appropriate nomenclature of 'chronic enteropathy associated with the SLCO2A1 gene' [CEAS] has been suggested. CEAS ulcers are characterised by multiple, circular or eccentric oblique, shallow lesions with discrete margins. The most frequently affected site of CEAS is the ileum, in contrast to 'cryptogenic multifocal ulcerous stenosing enteritis [CMUSE]', for which the most frequent site is the jejunum. Impaired prostaglandin utilisation is thought to cause the small intestinal mucosal damage observed in CEAS, CMUSE, and NSAID-induced enteropathy. This review article focuses on endoscopic and clinical features of genetically diagnosed CEAS, accumulated in a nationwide survey, and illustrates the observations in the format of an atlas.
Copyright © 2017 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  balloon-assisted enteroscopy; small intestine; video capsule endoscopy

Mesh:

Substances:

Year:  2017        PMID: 28510689     DOI: 10.1093/ecco-jcc/jjx068

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  13 in total

Review 1.  Roles of Organic Anion Transporting Polypeptide 2A1 (OATP2A1/SLCO2A1) in Regulating the Pathophysiological Actions of Prostaglandins.

Authors:  Takeo Nakanishi; Ikumi Tamai
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

2.  The organic anion transporter SLCO2A1 constitutes the core component of the Maxi-Cl channel.

Authors:  Ravshan Z Sabirov; Petr G Merzlyak; Toshiaki Okada; Md Rafiqul Islam; Hiromi Uramoto; Tomoko Mori; Yumiko Makino; Hiroshi Matsuura; Yu Xie; Yasunobu Okada
Journal:  EMBO J       Date:  2017-10-18       Impact factor: 11.598

Review 3.  Cryptogenic Multifocal Ulcerating Stenosing Enteropathy(CMUSE) and/or Chronic Non-specific Multiple Ulcers of the Small Intestine(CNSU) and Non-granulomatous Ulcerating Jejunoileitis (NGUJI).

Authors:  Ayaskanta Singh
Journal:  Curr Gastroenterol Rep       Date:  2019-09-10

4.  Clinical features of chronic enteropathy associated with SLCO2A1 gene: a new entity clinically distinct from Crohn's disease.

Authors:  Junji Umeno; Motohiro Esaki; Atsushi Hirano; Yuta Fuyuno; Naoki Ohmiya; Shigeyoshi Yasukawa; Fumihito Hirai; Shuji Kochi; Koichi Kurahara; Shunichi Yanai; Keiichi Uchida; Shuhei Hosomi; Kenji Watanabe; Naoki Hosoe; Haruhiko Ogata; Tadakazu Hisamatsu; Manabu Nagayama; Hironori Yamamoto; Daiki Abukawa; Fumihiko Kakuta; Kei Onodera; Toshiyuki Matsui; Toshifumi Hibi; Tsuneyoshi Yao; Takanari Kitazono; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2018-01-08       Impact factor: 7.527

5.  A male Korean who was diagnosed with chronic enteropathy associated with SLCO2A1 (CEAS): case report with literature review.

Authors:  Xi Sun; Naoki Hosoe; Ryoichi Miyanaga; Kayoko Kimura; Shinta Mizuno; Kaoru Takabayashi; Makoto Naganuma; Hironori Niizeki; Atsuhito Seki; Haruhiko Ogata; Takanori Kanai
Journal:  BMJ Open Gastroenterol       Date:  2018-10-23

6.  Successful azathioprine treatment in an adolescent with chronic enteropathy associated with SLCO2A1 gene: A case report.

Authors:  Keisuke Eda; Tatsuki Mizuochi; Yugo Takaki; Kosuke Ushijima; Junji Umeno; Yushiro Yamashita
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

7.  Characteristic Facial Appearance Was the Key to Diagnosing Chronic Enteropathy Associated with <i>SLCO2A1</i>-associated Primary Hypertrophic Osteoarthropathy.

Authors:  Akira Sonoda; Yasuhiro Wada; Kazumi Togo; Kazuhiro Mizukami; Yuta Fuyuno; Junji Umeno; Shin Fujioka; Kensuke Fukuda; Kazuhisa Okamoto; Ryo Ogawa; Tadayoshi Okimoto; Kazunari Murakami
Journal:  Intern Med       Date:  2019-10-15       Impact factor: 1.271

8.  A novel mutation in the SLCO2A1 gene, encoding a prostaglandin transporter, induces chronic enteropathy.

Authors:  Keisuke Jimbo; Toshiaki Okuno; Ryuichi Ohgaki; Kou Nishikubo; Yuri Kitamura; Yumiko Sakurai; Lili Quan; Hiromichi Shoji; Yoshikatsu Kanai; Toshiaki Shimizu; Takehiko Yokomizo
Journal:  PLoS One       Date:  2020-11-09       Impact factor: 3.240

9.  Chronic Enteropathy Associated with SLCO2A1 with Pachydermoperiostosis.

Authors:  Yoshikazu Tsuzuki; Ryutaro Aoyagi; Kazuya Miyaguchi; Keigo Ashitani; Hideki Ohgo; Minoru Yamaoka; Keisuke Ishizawa; Hidekazu Kayano; Tadakazu Hisamatsu; Junji Umeno; Naoki Hosoe; Takayuki Matsumoto; Hidetomo Nakamoto; Hiroyuki Imaeda
Journal:  Intern Med       Date:  2020-12-15       Impact factor: 1.271

Review 10.  The ATP-Releasing Maxi-Cl Channel: Its Identity, Molecular Partners and Physiological/Pathophysiological Implications.

Authors:  Ravshan Z Sabirov; Md Rafiqul Islam; Toshiaki Okada; Petr G Merzlyak; Ranokhon S Kurbannazarova; Nargiza A Tsiferova; Yasunobu Okada
Journal:  Life (Basel)       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.